Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Visionary Pharmaceuticals Awarded Phase 1 SBIR Grant

Published: Thursday, August 08, 2013
Last Updated: Thursday, August 08, 2013
Bookmark and Share
Company has been awarded grant to develop TH17 immunomodulators for inflammatory bowel disease.

Visionary Pharmaceuticals, Inc., has announced that the company has obtained a significant Phase 1 Small Business Innovation Research award “Development of RORγt Immunomodulators Targeting the TH17 Axis in IBD”.

The company is using the proceeds to develop novel small molecule retinoic acid related orphan receptor (ROR) modulators targeting TH17 T- lymphocytes in inflammatory bowel disease.

Visionary Pharmaceuticals has created an innovative drug discovery engine utilizing proprietary structure-based drug design technology to focus on nuclear hormone receptors.

The BindingSIGHTs platform encompasses an advanced suite of structural biology and chemical informatics computational tools.

BindingSIGHTs enables sophisticated in silico screening and structure-based drug design for molecular drug targets. With cell assays and deep expertise in nuclear receptor drug discovery Visionary Pharmaceuticals is currently developing several chemically diverse RORγt inverse agonists.

These compounds are potent, selective and demonstrate functional activity to ablate human TH17 differentiation and IL-17 cytokine secretion ex vivo.

“Nuclear hormone receptor modulators account for nearly 15% of all drugs sold in the US with $27 billion in annual sales. In this highly druggable class of targets RORγt inverse agonists represent a potential new source of blockbuster medications for significant unmet medical needs in autoimmune disease. With this grant we can now enable final optimization of our lead series as we move towards selection of an IND candidate.”, said Gordon Alton, Ph.D., President and CEO of Visionary.

Alton continued, “Obtaining this grant, especially under the current NIH budget pressures, reinforces the deep scientific credibility of our organization and rewards us for creating an innovative approach to treating inflammatory bowel disease.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.
Human Evolution Driven by Viruses
Study finds surprising percentage of protein adaptions in humans have been driven by viruses.
Earliest Sign of Alzheimer's Development Discovered
Researchers have identified the first physiological signs of late-onset Alzheimer's disease, underlining the importance of computational power in neurology.
Computational Method Offers Significant Boost in Finding New Cancer Targets
MIT and ARIAD Pharmaceuticals team have identified evidence of significant cancer mutations.
Drug Response Predicted by Cancer Cell Lines
Large-scale study could increase success rate of developing personalised cancer treatments.
Google and EI Partner for Next Generation of Coders
The Earlham Institute's open-source project for visualisation of biological data BioJS acts as mentor organisation for Google Summer of Code 2016.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!